CN1856508A - 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段 - Google Patents

针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段 Download PDF

Info

Publication number
CN1856508A
CN1856508A CNA038030926A CN03803092A CN1856508A CN 1856508 A CN1856508 A CN 1856508A CN A038030926 A CNA038030926 A CN A038030926A CN 03803092 A CN03803092 A CN 03803092A CN 1856508 A CN1856508 A CN 1856508A
Authority
CN
China
Prior art keywords
antibody
ser
thr
gly
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038030926A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯托·布里奥尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1856508A publication Critical patent/CN1856508A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNA038030926A 2002-01-30 2003-01-29 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段 Pending CN1856508A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002RM000049A ITRM20020049A1 (it) 2002-01-30 2002-01-30 Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
ITRM2002A000049 2002-01-30

Publications (1)

Publication Number Publication Date
CN1856508A true CN1856508A (zh) 2006-11-01

Family

ID=11456013

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038030926A Pending CN1856508A (zh) 2002-01-30 2003-01-29 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段

Country Status (17)

Country Link
US (2) US20050084845A1 (enExample)
EP (1) EP1476468B9 (enExample)
JP (1) JP4287280B2 (enExample)
KR (1) KR101002791B1 (enExample)
CN (1) CN1856508A (enExample)
AT (1) ATE407147T1 (enExample)
AU (1) AU2003208000B2 (enExample)
CA (1) CA2474801C (enExample)
DE (1) DE60323333D1 (enExample)
DK (1) DK1476468T3 (enExample)
EA (1) EA009861B1 (enExample)
ES (1) ES2314179T3 (enExample)
IT (1) ITRM20020049A1 (enExample)
NZ (1) NZ534922A (enExample)
RU (1) RU2004126238A (enExample)
WO (1) WO2003064473A2 (enExample)
ZA (1) ZA200406187B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939334A (zh) * 2007-12-17 2011-01-05 医疗技术研究局 C型肝炎病毒抗体
CN102264393A (zh) * 2008-12-22 2011-11-30 波莫纳·里切尔卡有限公司 作为治疗和预防hcv感染药物的抗hcv单克隆抗体
CN102859360A (zh) * 2010-03-01 2013-01-02 文森特·阿格内洛 Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物
CN104119436A (zh) * 2013-04-27 2014-10-29 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
CN102859360B (zh) * 2010-03-01 2016-12-14 文森特·阿格内洛 Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
WO2008107187A1 (en) * 2007-03-06 2008-09-12 Ribovax Biotechnologies S.A. Antibodies specific for rubella virus
CN101809033A (zh) 2007-07-25 2010-08-18 日本国立感染症研究所 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
KR20180001380U (ko) 2016-10-31 2018-05-10 대우조선해양 주식회사 해양구조물의 발로 작동시키는 캡스탄
CN118440204A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
US20230312744A1 (en) 2020-09-02 2023-10-05 The University Of Tokyo Modulatory Substance of Tumor Immune Microenvironment, and Preventive, Diagnostic and/or Therapeutic Utilization of the Same
US20250375498A1 (en) 2022-07-28 2025-12-11 The University Of Tokyo Neurotrimin function inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951646B1 (en) * 1998-07-21 2005-10-04 Genmab A/S Anti hepatitis C virus antibody and uses thereof
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
AU2001273363A1 (en) 2000-07-12 2002-01-21 General Instrument Corporation Method and apparatus for downloading objects via an inband channel with minimal subscriber impact
JP2004524829A (ja) * 2000-12-01 2004-08-19 アメリカ合衆国 Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101939334A (zh) * 2007-12-17 2011-01-05 医疗技术研究局 C型肝炎病毒抗体
CN101939334B (zh) * 2007-12-17 2015-01-14 医疗技术研究局 C型肝炎病毒抗体
CN102264393A (zh) * 2008-12-22 2011-11-30 波莫纳·里切尔卡有限公司 作为治疗和预防hcv感染药物的抗hcv单克隆抗体
CN102264393B (zh) * 2008-12-22 2013-09-11 波莫纳·里切尔卡有限公司 作为治疗和预防hcv感染药物的抗hcv单克隆抗体
CN102859360A (zh) * 2010-03-01 2013-01-02 文森特·阿格内洛 Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物
CN102859360B (zh) * 2010-03-01 2016-12-14 文森特·阿格内洛 Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物
US9719141B2 (en) 2010-03-01 2017-08-01 Vincent Agnello Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients
CN104119436A (zh) * 2013-04-27 2014-10-29 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
CN104119436B (zh) * 2013-04-27 2016-12-28 中国科学院上海生命科学研究院 抗丙型肝炎病毒的中和性全人单克隆抗体
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用

Also Published As

Publication number Publication date
KR20040077745A (ko) 2004-09-06
EP1476468B1 (en) 2008-09-03
WO2003064473A2 (en) 2003-08-07
EA200401081A1 (ru) 2005-10-27
US7727529B2 (en) 2010-06-01
JP4287280B2 (ja) 2009-07-01
JP2005531286A (ja) 2005-10-20
ITRM20020049A1 (it) 2003-07-30
CA2474801A1 (en) 2003-08-07
NZ534922A (en) 2008-07-31
EA009861B1 (ru) 2008-04-28
ES2314179T3 (es) 2009-03-16
CA2474801C (en) 2012-03-20
WO2003064473A3 (en) 2003-12-24
US20080241162A1 (en) 2008-10-02
US20050084845A1 (en) 2005-04-21
ZA200406187B (en) 2006-06-28
DE60323333D1 (de) 2008-10-16
EP1476468B9 (en) 2009-04-08
ATE407147T1 (de) 2008-09-15
AU2003208000B2 (en) 2010-05-20
EP1476468A2 (en) 2004-11-17
RU2004126238A (ru) 2005-04-20
KR101002791B1 (ko) 2010-12-21
ITRM20020049A0 (it) 2002-01-30
DK1476468T3 (da) 2009-01-19

Similar Documents

Publication Publication Date Title
CN1856508A (zh) 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段
CN1246335C (zh) 用于治疗il－18介导疾病的重组il－18拮抗物
CN100344970C (zh) 结合前列腺特异性膜抗原胞外域的抗体或其抗原结合部分、包含它们的试剂盒及其用途
CN1105728C (zh) 用于治疗il4介导疾病的重组il4抗体
CN1093881C (zh) 免疫原或诊断剂的制备及其获得免疫原或诊断试剂的方法
CN1163599C (zh) 抗gpiib/iiia重组抗体
CN1884303A (zh) SARS－CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
CN1839144A (zh) 兔单克隆抗体的人源化方法
CN101074261A (zh) Trail受体1和/或trail受体2特异性抗体及其应用
CN1656121A (zh) 人源化抗体及其制备方法
CN1622958A (zh) 促甲状腺素(tsh)受体的表位区域、其用途和针对该区域的抗体
CN1087681A (zh) 具有抗人体内病原菌感染的被动免疫力的新抗体
CN1073719A (zh) 非a和非b肝炎病毒的诊断及疫苗
CN1798769A (zh) 抗masp－2抗体
CN1663963A (zh) 杂合干扰素组合物及其使用方法
CN1852981A (zh) 抗血小板膜糖蛋白vi单克隆抗体
CN1283662C (zh) 拮抗性抗hFAS配基人类抗体及其片段
CN1642983A (zh) 抗C5aR抗体及其应用
CN1531554A (zh) 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
CN1551783A (zh) 治疗多发性骨髓瘤的方法
CN1078250C (zh) 抗免疫球蛋白等模式标本的重整形单克隆抗体
CN1768078A (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
CN1856503A (zh) 来源于c型肝炎病毒的肽
CN1273593C (zh) 丙型肝炎病毒多表位抗原的基因克隆及其编码序列
CN1653086A (zh) 新的肽组合物以及它们在制备抗丙肝病毒药物组合物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20090327

Address after: San Marino Dogana

Applicant after: Full antibody and biotechnology Co.,Ltd.

Address before: Italy.

Applicant before: Beal Ni Paula Beni Co.

Effective date of registration: 20090327

Address after: Italy.

Applicant after: Beal Ni Paula Beni Co.

Address before: Italy Rimini

Applicant before: Roberto Brioni

ASS Succession or assignment of patent right

Owner name: WHOLE ANTIBODY AND BIOTECHNOLOGY CO.,LTD.

Free format text: FORMER OWNER: BIONI PAULABENY CO.,LTD.

Effective date: 20090327

Owner name: BIONI PAULABENY CO.,LTD.

Free format text: FORMER OWNER: ROBERTO BRIONI

Effective date: 20090327

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication